16 November 2021 | Tuesday | News
Veeva Systems (NYSE: VEEV)today announced that it will expand Veeva OpenData's customer base data across Europe to connect new email, demographic and public inquiry data across the full spectrum of key healthcare stakeholders. With more data in Veeva CRM, OpenData helps biopharmaceutical sales teams eliminate data silos, reach new customers, and provide insights into more personalized interactions with healthcare providers (HCPs).
Adopted by more than 70 European customers and the world's top 20 pharmaceutical companies, OpenData helps teams in the field effectively maintain compliance through comprehensive and reliable data about each customer and their affiliations. Over the next year, OpenData will add several new data assets and hundreds of other data stewards in Europe to give life sciences companies a more complete and accurate view of their customer references, including coverage of:
"Adding curated email and reference data across a broader ecosystem of healthcare influencers will allow us to further orchestrate and personalize digital engagement during product launch," said David Andrew,CRM and Field force technology lead (CEMEA region) at Alnylam Pharmaceuticals. "Veeva OpenData's new insights are invaluable in our efforts to find and reach more of the correct HCP in rare disease areas."
"As medicine becomes more complex, the life sciences industry changes and engages with the entire healthcare ecosystem," said Oskar Möbert, vice president of OpenData Europe, Veeva Systems. "We continue to leverage innovative algorithms and add valuable reference data assets that are verified by hundreds of data stewards. By providing timely and accurate insights that support better engagement across the comprehensive healthcare ecosystem, we can help companies significantly improve patient care."
To learn more about Veeva OpenData, life sciences professionals can register for the upcoming Veeva Commercial & Medical Summit Connect Europe on November 18, 2021. A group of data leaders from Janssen, Novartis Gene Therapies and Pierre Fabre will share how they are working on data and analytics for the precision effort. More information and details of the program are available on veeva.com/eu/summit.